“Genes and Pathways Downregulated or Upregulated in CML Cells Treated with Imatinib and Nilotinib: Potential Targets for CML Diagnosis and Therapy”

https://pubmed.ncbi.nlm.nih.gov/38117080

The study has identified common genes and pathways that are downregulated or upregulated in chronic myeloid leukemia (CML) cells treated with imatinib and nilotinib, which have the potential to become target genes for diagnosis and therapy of CML patients.